• Symposium
  • biomodal presenter
  • In partnership with Illumina

The German Cancer Research Center (DKFZ) – Technical Talk

Join biomodal for a dynamic session led by Tom Charlesworth, Director of Market Strategy & Corporate Development
21 October 2024
11:00 am
to 12:00 pm
CET
German Cancer Research Center (DKFZ)

Presentations

Explore our resources

Register now

About the event

Tom will introduce the 6-base genome (A, T, C, G, 5mC, and 5hmC) delivered by a powerful new technology, duet evoC. The talk will focus on data demonstrating how the 6-base genome can improve biomarker detection, provide insight into regulatory dynamics and be used to predict gene expression and chromatin accessibility.

Presenting at the event

The 6-base genome reveals novel biomarkers and gene regulatory mechanisms ​

Tom Charlesworth

Director of Market Strategy & Corporate Development

biomodal

Discover how duet multiomics solution evoC reveals the power of the 6-base genome in one workflow. The combinatorial genetic and epigenetic technology provides single-base-resolution sequencing data that reveals standard four-base sequencing (A, C, G, and T), and distinguishes between 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).

This added resolution will allow greater power in detecting disease associations, identifying novel biomarkers, developing disease classifiers, and monitoring the progression of disease; even with limited samples such as cell-free DNA (cfDNA).

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Related resources

Attending from biomodal

Aziz Mustafa

Aziz Mustafa, PhD

Director of Sales and Business Development, Europe

Register now

DKFZ 21Oct24

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.

News

Events

biomodal logo

Discover

Explore

Connect

Legal

© 2024 biomodal. All rights reserved.
LinkedIn
Cambridge Epigenetix is now biomodal
Read more